Mintayax (Pemetrexed)

Pemetrexed, the active ingredient in Mintayax, is an antifolate presented as an injection solution for intravenous use. It is indicated for the treatment of malignant pleural mesothelioma and for non‑squamous non‑small cell lung cancer in adult patients, typically as part of combination or maintenance therapy.

GNH USA supplies Mintayax as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Pemetrexed is employed in oncology to target cancers that depend on folate metabolism. - Malignant pleural mesothelioma: improves overall survival when combined with cisplatin in adult patients. - Non‑squamous non‑small cell lung cancer: used as maintenance therapy after first‑line platinum‑based chemotherapy.

Adverse reactions to Mintayax vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: gastrointestinal upset often occurring during treatment cycles. - Anemia: reduction in red blood cell count leading to low hemoglobin. - Neutropenia: decreased neutrophil levels increasing infection risk. - Elevated liver enzymes: transient rise in ALT/AST values. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Interstitial lung disease: inflammation of lung tissue that can be life‑threatening. - Severe neutropenia: profound drop in neutrophils requiring hospitalization. - Thrombocytopenia: low platelet count leading to bleeding complications. - Renal failure: acute kidney injury necessitating supportive care. - Anaphylactic reaction: severe hypersensitivity requiring immediate intervention. - Hepatic failure: marked liver dysfunction with jaundice or coagulopathy.

When using Mintayax, several precautionary measures should be observed to minimise toxicity. - Monitor blood counts: perform regular CBC tests to detect myelosuppression. - Assess renal function: evaluate creatinine clearance before each dose. - Evaluate hepatic function: check liver enzymes and bilirubin levels regularly. - Avoid concurrent nephrotoxic agents: limit use of drugs that may impair kidney function. - Provide folic acid and vitamin B12 supplementation: recommended to reduce hematologic toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mintayax may interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Cisplatin: combined use can increase renal toxicity. - NSAIDs: may exacerbate kidney impairment when given together. - Live vaccines: immunosuppression can raise risk of infection. - High‑dose folic acid antagonists: can diminish therapeutic effect. - Radiation therapy: concurrent administration may intensify myelosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk due to platelet effects. - Other myelosuppressive agents: monitor blood counts closely. - Proton pump inhibitors: may affect drug clearance. - Allopurinol: potential for enhanced hematologic toxicity. - ACE inhibitors: watch for additive renal effects.